CollPlant Biotechnologies Ltd. (CLGN)
$
1.79
-0.11 (-6.15%)
Key metrics
Financial statements
Free cash flow per share
-0.7876
Market cap
22.8 Million
Price to sales ratio
9.1966
Debt to equity
0.3160
Current ratio
3.6558
Income quality
0.8181
Average inventory
546.5 Thousand
ROE
-1.0203
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
CollPlant Biotechnologies Ltd. is a forward-thinking company in the fields of regenerative and aesthetic medicine, with a focus on three-dimensional (3D) bioprinting technologies used for creating tissues and organs. The operating income ratio is -33.50 indicating the company's operational profitability margin. Based in Rehovot, Israel, the company has established its presence across the United States, Canada, and Europe, leveraging its proprietary plant-based genetic engineering technology to produce recombinant type I human collagen. The products offered by CollPlant include innovative BioInks for 3D bioprinting of tissues and organs, as well as dermal fillers and soft tissue fillers aimed at treating wrinkles. Additionally, it has developed 3D bioprinted breast implants designed for breast tissue regeneration, injectable implants that facilitate breast tissue regeneration, and a 3D bioprinted regenerative soft tissue matrix. The company also provides VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care solution for managing deep surgical incisions and various types of chronic wounds. The gross profit ratio is -4.17 reflecting the efficiency of the company’s production and sales operations. Furthermore, the company reported depreciation and amortization expenses of $1,038,000.00 reflecting the wear and tear of its assets, while showcasing its financial health with an interest income of $738,000.00. Its stock is identified with the symbol 'CLGN' in the market. As a small-cap player with a market capitalization of $22,761,640.00 CollPlant Biotechnologies Ltd. is positioned as a key player in the Biotechnology industry, driving innovation and growth within the market landscape. The stock is affordable at $2.52 suitable for budget-conscious investors, even though it has a low average trading volume of 99,434.00 indicating lower market activity. CollPlant's strategic collaborations with notable organizations such as 3D Systems Corporation, CellInk (a BICO Group company), and the Advanced Regenerative Manufacturing Institute enhance its capabilities and market reach. Additionally, partnerships with AbbVie and the Technion Institute of Technology underscore its commitment to advancing medical aesthetics and regenerative medicine. As it navigates the evolving Healthcare sector, CollPlant continues to contribute significantly to innovative solutions that address various medical challenges.
Is CollPlant Biotechnologies Ltd. (CLGN) a good investment?
Investing in CollPlant Biotechnologies Ltd. (CLGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is CollPlant Biotechnologies Ltd. (CLGN)'s stock forecast?
Analysts predict CollPlant Biotechnologies Ltd. stock to fluctuate between $1.31 (low) and $4.98 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is CollPlant Biotechnologies Ltd.'s market capitalization?
As of 2025-12-12, CollPlant Biotechnologies Ltd.'s market cap is $22,761,640, based on 12,716,000 outstanding shares.
How does CollPlant Biotechnologies Ltd. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., CollPlant Biotechnologies Ltd. has a Lower Market-Cap, indicating a difference in performance.
How can I buy CollPlant Biotechnologies Ltd. (CLGN) stock?
To buy CollPlant Biotechnologies Ltd. (CLGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CLGN. Place an order (Market, Limit, etc.).
What is the best time to invest in CollPlant Biotechnologies Ltd.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has CollPlant Biotechnologies Ltd. stock ever split?
CollPlant Biotechnologies Ltd.'s last stock split was 2:3 on 2016-12-01.
How did CollPlant Biotechnologies Ltd. perform in the last earnings report?
Revenue: $515,000 | EPS: -$1.45 | Growth: 133.87%.
Where can I find CollPlant Biotechnologies Ltd.'s investor relations reports?
Visit https://www.collplant.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for CollPlant Biotechnologies Ltd.?
You can explore historical data from here
What is the all-time high and low for CollPlant Biotechnologies Ltd. stock?
All-time high: $23 (2021-11-16) | All-time low: $1.31 (2025-07-01).
What are the key trends affecting CollPlant Biotechnologies Ltd. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics center scheduled to become operational this quarter and under new commercial leadership for this region Recent developments suggest CollPlant's rhCollagen will have a significant contribution towards innovation in the areas of non-animal alternatives for medical and research Plan for cost reductions and program prioritization in place to extend cash runway REHOVOT, Israel , Nov. 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the third quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer, remarked, "CollPlant continued to advance innovation this quarter beyond its core development programs.
prnewswire.com
-- New North American logistics center will provide expanded distribution for CollPlant's rhCollagen and BioInks as well as enable logistical efficiencies -- REHOVOT, Israel , Oct. 27, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the expansion of its distribution footprint into North America through a new partnership with a U.S.-based logistics center. Scheduled to become operational this quarter, the logistics hub will provide full cGMP-compliant storage and distribution services and will serve as a clinical supply depot.
prnewswire.com
New U.S.-based role to support growth strategy, partnerships, and scaling of rhCollagen product platforms REHOVOT, Israel , July 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr.
prnewswire.com
REHOVOT, Israel , May 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,200,002 of the Company's ordinary shares at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company's ordinary shares at an exercise price of $3.00 per share.
prnewswire.com
REHOVOT, Israel , May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics.
seekingalpha.com
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2024 Earnings Conference Call March 26, 2025 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Swayampakula Ramakanth - H.C.
See all news
